Vasculitis - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 94
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V4A0A800122EN
Leaflet:

Download PDF Leaflet

Vasculitis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Vasculitis - Pipeline Review, H2 2016’, provides an overview of the Vasculitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasculitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Vasculitis
  • The report reviews pipeline therapeutics for Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Vasculitis therapeutics and enlists all their major and minor projects
  • The report assesses Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Vasculitis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Vasculitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Vasculitis Overview
Therapeutics Development
Pipeline Products for Vasculitis - Overview
Pipeline Products for Vasculitis - Comparative Analysis
Vasculitis - Therapeutics under Development by Companies
Vasculitis - Therapeutics under Investigation by Universities/Institutes
Vasculitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Vasculitis - Products under Development by Companies
Vasculitis - Products under Investigation by Universities/Institutes
Vasculitis - Companies Involved in Therapeutics Development
AnGes MG, Inc.
ChemoCentryx, Inc.
Cipla Ltd.
Coherus BioSciences, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Hemostemix Ltd
Johnson & Johnson
K-Stemcell Co., Ltd.
Panacea Biotec Limited
Pfizer Inc.
Sandoz International GmbH
Teijin Pharma Limited
Vasculitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCX-168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-1355 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirukumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Thromboangiitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stempeucel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vasculitis - Dormant Projects
Vasculitis - Product Development Milestones
Featured News & Press Releases
Jun 06, 2016: Phase III study shows Roche’s Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA)
May 30, 2016: DCGI Gives Limited Approval to Market FIRST Allogeneic Cell Therapy Product in India Stempeutics puts India on the World map of Regenerative Medicine
Nov 25, 2015: GSK announces start of phase III study of sirukumab in Giant Cell Arteritis
Jun 01, 2015: Stempeutics Receives Orphan Drug Designation (ODD) in the European Union for its Novel Stem Cell Drug "Stempeucel" for the Treatment of Thromboangiitis Obliterans
Mar 23, 2015: Stempeutics Receives Advanced Therapy Medicinal Product (ATMP) Classification From European Medicines Agency (EMA) for its Novel Stem Cell Drug 'Stempeucel'
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal
May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress
Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis
Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Vasculitis, H2 2016
Number of Products under Development for Vasculitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Vasculitis - Pipeline by AnGes MG, Inc., H2 2016
Vasculitis - Pipeline by ChemoCentryx, Inc., H2 2016
Vasculitis - Pipeline by Cipla Ltd., H2 2016
Vasculitis - Pipeline by Coherus BioSciences, Inc., H2 2016
Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Vasculitis - Pipeline by GlaxoSmithKline Plc, H2 2016
Vasculitis - Pipeline by Hemostemix Ltd, H2 2016
Vasculitis - Pipeline by Johnson & Johnson, H2 2016
Vasculitis - Pipeline by K-Stemcell Co., Ltd., H2 2016
Vasculitis - Pipeline by Panacea Biotec Limited, H2 2016
Vasculitis - Pipeline by Pfizer Inc., H2 2016
Vasculitis - Pipeline by Sandoz International GmbH, H2 2016
Vasculitis - Pipeline by Teijin Pharma Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Vasculitis - Dormant Projects, H2 2016
Vasculitis - Dormant Projects (Contd..1), H2 2016

LIST OF FIGURES

Number of Products under Development for Vasculitis, H2 2016
Number of Products under Development for Vasculitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AnGes MG, Inc.
ChemoCentryx, Inc.
Cipla Ltd.
Coherus BioSciences, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Hemostemix Ltd
Johnson & Johnson
K-Stemcell Co., Ltd.
Panacea Biotec Limited
Pfizer Inc.
Sandoz International GmbH
Teijin Pharma Limited
Skip to top


Septic Shock - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 92 pages

Ask Your Question

Vasculitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: